| Erin June Bowers, AUD | |
|
118 Lee St, Petersburg, WV 26847-9408 | |
| (304) 668-9055 | |
| Not Available |
| Full Name | Erin June Bowers |
|---|---|
| Gender | Female |
| Speciality | Qualified Audiologist |
| Experience | 3 Years |
| Location | 118 Lee St, Petersburg, West Virginia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1578228904 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | (* (Not Available)) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mobile Audiology Of West Virginia Pllc | 4981967346 | 3 |
News Archive
Researchers have identified 23 new longevity genes by screening the genome of Caenorhabditis elegans, a small worm that is used as a model organism in genetics studies. The findings are reported in the inaugural issue of PLoS Genetics.
Shire plc, the global specialty biopharmaceutical company, announces that Health Canada has approved VYVANSE® (lisdexamfetamine dimesylate capsules) for the treatment of attention deficit hyperactivity disorder (ADHD) in adolescents and adults.
Laparoscopic ventral rectoplexy may reduce sexual dysfunction in women with complex posterior floor prolapse, say researchers who found many patients appreciated having postoperative investigation of their symptoms.
Kamada has announced today positive data from its Phase II study evaluating inhaled Alpha-1 Antitrypsin (AAT) delivered via an Investigational eFlow Nebulizer System (PARI Pharma GmbH), in the treatment of cystic fibrosis. The results demonstrate the product has an excellent safety profile and shows promising signs of efficacy, as indicated by a reduction in lung inflammation.
› Verified 2 days ago
| Provider Name | Mobile Audiology Of West Virginia Pllc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1124537766 PECOS PAC ID: 4981967346 Enrollment ID: O20180417001828 |
News Archive
Researchers have identified 23 new longevity genes by screening the genome of Caenorhabditis elegans, a small worm that is used as a model organism in genetics studies. The findings are reported in the inaugural issue of PLoS Genetics.
Shire plc, the global specialty biopharmaceutical company, announces that Health Canada has approved VYVANSE® (lisdexamfetamine dimesylate capsules) for the treatment of attention deficit hyperactivity disorder (ADHD) in adolescents and adults.
Laparoscopic ventral rectoplexy may reduce sexual dysfunction in women with complex posterior floor prolapse, say researchers who found many patients appreciated having postoperative investigation of their symptoms.
Kamada has announced today positive data from its Phase II study evaluating inhaled Alpha-1 Antitrypsin (AAT) delivered via an Investigational eFlow Nebulizer System (PARI Pharma GmbH), in the treatment of cystic fibrosis. The results demonstrate the product has an excellent safety profile and shows promising signs of efficacy, as indicated by a reduction in lung inflammation.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Erin June Bowers, AUD 118 Lee St, Petersburg, WV 26847-9408 Ph: (304) 668-9055 | Erin June Bowers, AUD 118 Lee St, Petersburg, WV 26847-9408 Ph: (304) 668-9055 |
News Archive
Researchers have identified 23 new longevity genes by screening the genome of Caenorhabditis elegans, a small worm that is used as a model organism in genetics studies. The findings are reported in the inaugural issue of PLoS Genetics.
Shire plc, the global specialty biopharmaceutical company, announces that Health Canada has approved VYVANSE® (lisdexamfetamine dimesylate capsules) for the treatment of attention deficit hyperactivity disorder (ADHD) in adolescents and adults.
Laparoscopic ventral rectoplexy may reduce sexual dysfunction in women with complex posterior floor prolapse, say researchers who found many patients appreciated having postoperative investigation of their symptoms.
Kamada has announced today positive data from its Phase II study evaluating inhaled Alpha-1 Antitrypsin (AAT) delivered via an Investigational eFlow Nebulizer System (PARI Pharma GmbH), in the treatment of cystic fibrosis. The results demonstrate the product has an excellent safety profile and shows promising signs of efficacy, as indicated by a reduction in lung inflammation.
› Verified 2 days ago